|
|
|
|
|
|
|
|
|
|
|
 
|
Pancreas Cancer
News and Archives |
|
|
GenVec Presents Preliminary
Dose Escalation Data from Study Combining TNFerade(TM) with Chemotherapy
and Radiation in Patients With Locally Advanced Pancreatic Cancer GenVec, Inc., a biopharmaceutical company, announced preliminary data from the dose escalation portion of a Phase II study using TNFerade(TM) in combination with chemotherapy and radiation in patients with locally advanced, inoperable pancreatic cancer. The results, presented Sunday, June 1st in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, indicated that TNFerade, when used in combination with standard chemotherapy and radiation, was well tolerated at the two dose levels evaluated to date. Local control or stabilization of the treated tumors was also seen in 11 of the 17 evaluable patients (65%) as reported by an independent radiology laboratory (4 partial responses, 2 minor responses, 5 stable disease). Following treatment, two patients with previously inoperable tumors were able to have their cancers removed surgically with no evidence of cancer in the surrounding tissue. One of these patients showed a pathological complete response (no evidence of viable tumor cells). ...full article |
||
|
||
|
For educational
purposes only; not to be relied upon Please read Pancreatica Disclaimer |
||
 Home | In The News | Links | Newswire | Donations FAQ | Clinical Trials Database | Research Resources | About Us |
||
|
|
||
|
www.pancreatica.org |
||